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Immunoglobulin A1 proteases (IgAPs) are a family of enzymatic virulence factors secreted 
from a wide variety of pathogenic bacteria known to infect human mucosal surfaces. Once 
secreted, IgAPs cleave and inactivate the predominant mucosal antibody, immunoglobulin A1 
(IgA1), to hinder the host’s adaptive immune response. As such, these enzymes are heavily 
implicated in these species’ pathogenicities. Efforts are therefore underway to understand how 
IgAPs select for and cleave IgA1 to aid in the development of drugs to treat bacterial lower 
respiratory tract infections, among other clinical and biochemical applications. 
The IgAP secreted from Haemophilus influenzae is of particular interest due to its high 
specificity for IgA1. Since its crystal structure was solved over a decade ago, there has been slow 
progress in uncovering its mechanism of substrate recognition and the structure-function 
relationships underlying these mechanisms. This has been due in part to problems that arise from 
transitioning the protein expression system from that in the native host, H. influenzae, to one more 
amenable to large-scale enzyme production. To this end, my thesis details the successful 
development and verification of two H. influenzae IgAP expression and purification systems, one 
in Pichia pastoris and the other in Escherichia coli. With these new enzyme sources, future studies 
can take a deeper dive into the biochemical intricacies of the H. influenzae IgAP, with the hope of 
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Section 1 – Immunoglobulin A1 Proteases 
1.1 – Biomedical Significance 
 Lower respiratory tract infections (LRTIs) are one of the global leading causes of death for 
all ages,1 with individuals lacking adequate health care access,2 infants,3 the elderly,3 and the 
immunocompromised being most susceptible to the disease and its outcomes.4,5 The vast majority 
of LRTIs are caused by the bacterial pathogens Streptococcus pneumoniae and Haemophilus 
influenzae.1,2 Because LRTIs resulting from bacterial infection, particularly S. pneumoniae, are 
typically more serious and have a higher risk of mortality, antibiotics are often prescribed 
preemptively even though symptoms may not be related to LRTIs or may be due to viruses.6 This 
consequently escalates the global issue of antibiotic resistance.7 With three LRTI-associated 
bacterial pathogens, S. pneumoniae, H. influenzae, and Neisseria gonorrhoeae, already identified 
by the World Health Organization as top-priority concerns for antibiotic resistance,8 the 
development of alternative treatments for LRTIs is of great importance. 
 
1.2 – Immunoglobulin A1 Proteases as Bacterial Virulence Factors 
 Immunoglobulin A1 proteases (IgAPs) are a family of proteases which cleave 
immunoglobulin A1 (IgA1), the main antibody protecting mucosal surfaces.9,10 Because of IgA1’s 
role in defending lower respiratory tract surfaces, LRTI-associated bacteria often use IgAPs as a 
virulence factor to aid in immunosuppression and tissue colonization.9 
IgA1 is cleaved at its hinge region (Fig. 1.2.1a, red arrow), the linker between its antigen-
binding and immune-system-inducing domains.9,10 By decoupling the processes of pathogen 
detection and immune reaction, IgAPs are able to effectively subdue and subvert the adaptive 
immune response.9,10 All IgAPs cleave IgA1 C-terminal to a hinge-region proline, although IgAPs 
produced from different species or isozymes found within a single species may cleave at separate 
hinge sites (Fig. 1.2.1b).9 Once IgA1 has been cleaved, free antigen-binding domains coat the 
bacterium surface, protecting the pathogen from opsonization by competing with intact IgA1 for 
epitope binding.1112 A more detailed description of the general features of monomeric and 






These two means of protection offered by IgAPs highlight the enzymes’ importance in the 
infection pathway of LRTI-associated pathogens. The fact that pathogenicities of H. influenzae 
and N. gonorrhoeae clinical isolates were determined solely by the production of functional 
enzyme strongly suggests that IgAPs are critical to establishing successful infections.13–15 This 
likewise supports the use of IgAPs as the next set of antibiotic drug targets to treat bacterial 
LRTIs.9,14 As such, a deeper understanding of how IgAPs function at a molecular and atomic level 




Figure 1.2.1 – General reaction catalyzed by IgAP. a) Reaction overview: IgAPs cleave IgA1 (PDB 3CHN) at 
the heavy-chain hinge region (red arrow); Although the reaction is depicted with monomeric IgA1 for simplicity, 
the same site is cleaved in the secreted dimeric IgA1 (Section 1.6); L/L’ and H/H’ represent the light and heavy 
chains, respectively; H1/H2 are the two heavy-chain fragments after cleavage; IgAP-producing species of highest 
clinical interest are in green. b) Cleavage sites of several IgAPs: Primary sequence of the IgA1 hinge is shown 
with residues numbered according to Toraño and Putnam;12 the enzyme of interest in this thesis is the Type 1 H. 
influenzae IgAP and its cleavage site is indicated by the large arrow. 
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1.3 – The Immunoglobulin A1 Protease Family 
 Although all IgAPs have the same general function, there are stark differences in enzyme 
structure and mechanism between some members of the IgAP family. Each family member can be 
classified under one of the following three categories based on their catalytic mechanism: those 
involving activated serine, cysteine, or metal-activated nucleophiles.9 Evidence for the existence 
of each class was mainly based on the effects of general protease inhibitors on these enzymes, with 
additional support from structural homology to other protease types and primary-sequence 
functional motifs.9 In particular, serine IgAPs are inactivated by serine-specific peptides like prolyl 
boronic acid motifs,16 cysteine IgAPs with cysteine-specific inhibitors like iodoacetamide,17 and 
metal-dependent IgAPs with metal chelators like ethylenediaminetetraacetic acid (EDTA).18 In 
addition, cysteine IgAPs require reducing agent to retain activity.17 
Given the lack of primary sequence homology between each enzyme class, IgAPs are likely 
products of convergent evolution.9 This is not surprising as there is a great evolutionary advantage 
in cleaving IgA1 to facilitate infection.13–15 Structural divergence within the IgAP family is 
particularly evident when comparing the globular-domain architecture of the S. pneumoniae metal-
dependent IgAP19 to the elongated rod-like H. influenzae serine IgAP.20 Unfortunately, this means 
that structures of at least three representative IgAPs, one from each mechanism class, will be 
needed to gain a general understanding of this enzyme family. Furthermore, we can expect 
inhibitors specific to one enzyme to have limited applicability to members of other mechanism 
classes. With this in mind, let’s take a brief dive into the current progress of IgAP therapeutics and 
what needs to be done to continue their development. 
 
1.4 – Preliminary Immunoglobulin A1 Protease Inhibitors 
 Ever since the discovery of IgAPs, and their role in bacterial pathogenesis, there has been 
rising interest in developing IgAP inhibitors to treat diseases caused by IgAP-secreting pathogens. 
The collaborative efforts of synthetic organic chemists alongside cell biologists have led to the 
discovery of many novel small-molecule inhibitors, which act on a variety of IgAPs. 
The first set of inhibitors were designed to inhibit the N. gonorrhoeae serine IgAP by 
mimicking the IgA1 hinge-region primary sequence.21 Despite being a competitive active-site 
inhibitor, it did not inhibit the H. influenzae serine protease,21 which likely shares a conserved 
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active site to the N. gonorrhoeae IgAP based on its homologous primary sequence and identical 
structural elements.9 This highlights the need for high-resolution structural information, even 
within an IgAP class, as small structural differences clearly lead to different biochemical 
properties. These hinge-region peptides were further improved by brute-force optimization, 
leading to the development of inhibitors with low-micromolar half-maximal inhibitory 
concentrations (IC50).22 A similar methodology used prolyl boronic acids to develop hinge-peptide 
mimics for N. gonorrhoeae and H. influenzae IgAPs.16 As these molecules closely resembled one 
of the reaction’s transition states, they showed much stronger inhibition compared to the previous 
molecules, with inhibition constants (Kd) in the low-nanomolar range.16 
Non-active-site IgAP inhibitors were only discovered fairly recently, a few decades after 
the initial set of inhibitors were established, when a semi-high-throughput inhibitor screening 
method using gold nanoparticles was developed.23 The first inhibitors for the S. pneumoniae metal-
dependent IgAP were discovered using this method.23 A second high-throughput inhibitor 
screening method was developed using fluorescent probes, leading to the discovery of several 
allosteric inhibitors of the H. influenzae IgAP.24,25 
Unfortunately, none of these competitive or allosteric inhibitors have been further 
enhanced or characterized since their initial discovery. This has been largely due to the lack of 
high-resolution structural information for many of the enzymes targeted, which prevented the use 
of structure-based drug design strategies for drug optimization. 
 
1.5 – Immunoglobulin A Nephropathy 
The clinical relevance of IgAPs is not only limited to LRTIs and inhibitor design. Instead 
of being thought of as a drug target, IgAPs can be viewed as a protein-based drug for the treatment 
of immunoglobulin A nephropathy (IgAN). IgAN is a chronic renal disease characterized by the 
accumulation of immunoglobulin aggregates, primarily composed of IgA1, in kidney 
glomeruli.26,27 As these aggregates impede glomerular filtration, IgAN is often comorbid with other 
systemic diseases and complications, with the disease eventually leading to kidney failure.28 Due 
to the unknown and multi-faceted factors underlying IgAN, current treatment options have been 
unable to treat the underlying causes of the disease, only providing temporary relief by slowing 
down IgA1 buildup rather than removing existing immunoglobulin aggregates.28  
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Owing to their IgA1-degrading capabilities, IgAPs have promise as an IgAN therapeutic 
as they may be able to reverse symptoms by directly targeting the symptoms’ source.29 This 
potential was supported in a proof-of-concept experimental mouse model. To simulate the kidneys 
of chronic IgAN patients, human IgA1 aggregates were deposited into mouse glomeruli via the 
bloodstream.30 These aggregates were then effectively cleared following injections of H. 
influenzae IgAP.30 Similar kidney mouse models were used to show the viability of N.  
gonorrhoeae and Neisseria meningitidis IgAPs for IgAN treatment, recapitulating the same 
promising results.31 
 The use of IgAPs as an IgAN therapeutic provides two benefits in addition to the one 
previously stated. Some IgAPs have high substrate specificity, evident by their inability to cleave 
the IgA1 hinge peptide in isolation.32–34 This will reduce the likelihood of off-target effects, a 
frequent concern for small-molecule therapeutics.35 A second layer of substrate specificity may 
also be obtained by engineering IgAPs to recognize aggregated IgA1 over circulating or mucosal 
IgA1, as these molecules typically have under-glycosylated O-linked glycans, a structural variation 
that is thought to be the molecular cause of IgAN.27 
 As promising as this appears, these proof-of-concept mouse models failed to consider side-
effects associated with the enzyme’s high immunogenicity, as the enzyme has bacterial origin.29 
Engineering IgAPs, or any enzyme for that matter, to recognize alternate forms of its substrate is 
also not an easy feat. An in-depth understanding of IgAP structure, regions of immunogenicity, as 
well as properties of the IgAP-IgA1 interaction are all needed to redesign IgAPs into a clinically 
viable protein-based therapeutic. 
 
1.6 – Secretory and Serum Immunoglobulin A1 
 To fully appreciate the nuances and potential problems involved in moving IgAP research 
towards LRTI treatment, where the aim is to weaken or prevent IgAP-IgA1 interactions, or IgAN 
treatment, where the aim is to create more specific and stronger interactions, we must first take 
into account the structures of the physiologically relevant forms of IgA1. 
 Although IgA1 is found in serum and on mucosal surfaces, its major quaternary state differs 
between these environments.36 Serum IgA1 is mainly monomeric (Fig. 1.6.1a), while mucosal 
IgA1 primarily takes on a dimeric form (Fig. 1.6.1c).36 As IgA1 has the ability to form oligomeric 
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states as a part of its secretion pathway, through its association with other polypeptide chains, 
mucosal  IgA1 is secreted as a mixture of oligomeric states, primarily of the dimeric form, but with 
small populations of larger oligomers up to and including a pentameric state.37  
A brief summary of the secretion pathway for IgA1 is as follows: mucosal B cells produce 
and export the immature dimeric IgA1 precursor (Fig. 1.6.1b) out into the extracellular space 
basolateral to the mucosal epithelial lining.38 This precursor consists of two covalently linked 
monomeric IgA1 molecules attached by their constant region to a separate joining chain (J-
chain).38 Receptors present on the basolateral epithelial surface recognize and transcytose this 
precursor to the apical surface.38 Through this process, this dimeric precursor reaches maturation 
by combining with the transcytosis receptor’s ectodomain, which forms the secretory component 
(SC) of the mature dimer.37 Larger secreted oligomers can also form during transcytosis, whereby 
additional IgA1 monomers add to the existing dimeric scaffold.37 
When we eventually wish to apply IgAP research towards the two previously stated clinical 
end goals, it will be important to identify the most physiologically relevant form of IgA1 under 
each situation. As IgAP inhibitors should be designed to function on mucosal surfaces, the 
structure-function relationship of the dimeric IgA1-IgAP interaction should be the focus of that 
research. Under a similar logic, IgAPs designed to treat IgAN should be developed with a focus 
on the monomeric IgA1-IgAP interaction. That being said, IgAPs are able to recognize and cleave 
both monomeric and dimeric IgA1.31 Although a comparison between the kinetics and binding 
interactions of IgAPs with each form of IgA1, including oligomers larger than a dimer, have yet 
to be done, monomeric IgA1 still remains the easiest substrate to characterize for initial studies 
from both an economic and structural standpoint. As such, my thesis will use myeloma-produced 
monomeric IgA1 (Athens Research & Technology) for all experiments involving IgA1. 
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Figure 1.6.1 – Oligomeric forms of IgA1. a) Monomeric IgA1 (PDB 3CHN). The heavy and light chains are colored according to Fig. 
1.2.1a. b) Secreted by basolaterally located B cells, this immature dimeric IgA1 consists of two IgA1 monomers covalent linked via 
their constant region to the joining chain (J-chain). c) The mature IgA1 dimer found in mucosal secretions. The secretory component 
(SC) is added during the maturating transcytosis process.  
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1.7 – The Haemophilus influenzae Immunoglobulin A1 Protease 
 Of all of the IgAPs, the H. influenzae IgAP (HI-IgAP) is currently the most understood as 
it is the only IgAP with a published high-resolution structure (Fig. 1.7.1).20 This makes it a good 
starting point for investigating how IgAPs function. Unfortunately since the discovery of this 
crystal structure over a decade ago, there has been little to no progress in uncovering the deeper 
workings of the enzyme. This has been largely due to barriers in transitioning the protein 
expression system from the H. influenzae native system, previously used as the enzyme source to 
solve the crystal structure,20 to one more suitable for large-scale enzyme production. Fortunately, 
the results of my research have overcome this barrier, providing a foundation for future research 
into the biochemical intricacies of the HI-IgAP. 
This thesis will first outline the aforementioned barrier and previous unsuccessful attempts 
at overcoming it (Section 2). The development and verification of two new protein-production 
systems, one in Pichia pastoris (Section 3) and the other in Escherichia coli (Section 4), will be 
described, followed by a brief recap and discussion of future research aims (Section 5).  
  
Figure 1.7.1 – HI-IgAP crystal 
structure (PDB 3H09).25 
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Section 2 – Previous H. influenzae Immunoglobulin A1 Protease Expression Systems 
 To understand the inherent problems in moving the protein production system from H. 
influenzae to one more optimized for protein production, we must first appreciate some nuances 
of the H. influenzae IgAP (HI-IgAP) secretion pathway and crystal structure. 
 
2.1 – Secretion Pathway of the Haemophilus influenzae Immunoglobulin A1 Protease 
 As H. influenzae is Gram-negative, secreted proteins must cross both inner and outer cell 
membranes before they exit into the extracellular space.39 Although there are many secretion 
pathways available for Gram-negative bacteria, the HI-IgAP is secreted using the Type Va 
autotransporter system (Fig. 2.1.1):39  
The newly translated pre-pro-peptide contains an N-terminal signal peptide that is 
recognized by a protein complex associated with the inner membrane, the Sec complex, which  
translocates the protein into the periplasm.39 During this process, the signal peptide is cleaved to 
form the pro-peptide.39 Instead of using existing cellular machinery to cross the outer membrane, 
the C-terminal region of the pro-peptide freely folds into a beta barrel, which embeds itself into 
the outer membrane.39 The N-terminal region of the pro-peptide is then fed through the outer 
membrane with the help of one or more of these C-terminal β-domains, the specifics of which 
remain unclear, and the fully folded N-terminal protease domain is then released following 
membrane-bound folding and autoproteolysis.39 It is this N-terminal domain which constitutes the 
active protease, whose structure was determined by crystallography (Fig. 1.7.1).20 Part of the 
impetus to develop a non-native protein production system was the need to investigate inactive 
variants, which would have been impossible to produce in H. influenzae given the need for 










Figure 2.1.1 – Schematic of the HI-IgAP Type Va secretion pathway. This figure traces the autotransporting 
path of HI-IgAP from the cytosolic pre-pro-peptide, through to the periplasmic pro-peptide, and finally to the 
fully active protease (Fig. 1.7.1). The signal peptide and beta barrel are depicted in purple and yellow, 
respectively. Residues are numbered based on UniProtKB entry #P45384. 
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2.2 – The Protein-Production Quandary 
 The crystal structure of the secreted protease (Fig. 1.7.1) follows a typical fold for Type 
Va autotransporters,20,39 with an N-terminal functional domain linked to a characteristically 
elongated C-terminal beta helix.39 Despite having high structural homology to HI-IgAP, other 
proteins under the Type Va autotransporter family have vastly different functions, ranging from 
being a cell-cell adhesion molecule for biofilm formation40 to proteases that, like HI-IgAP, aid in 
bacterial pathogenicity, albeit using differing mechanisms.41,42 Again, this highlights the need for 
high-resolution structural information to understand how IgAPs work and what elements make 
them function differently to these structurally homologous proteins. 
The HI-IgAP N-terminal domain has a chymotrypsin-like fold and is where the active-site 
serine is located.20 The protease’s C-terminal fold seems to confer specificity towards IgA1 by 
using several loops that protrude from the beta helix to selectively interact with the IgA1 constant 
fragment, as supported by crude molecular-docking experiments.20 Beta helices are very common 
among other proteins in the Type Va autotransporter family, likely functioning as a folding nucleus 
to allow for protein folding following autoproteolysis starting from the C-terminus towards the N-
terminal protease domain.39  
 Problems with the recombinant production of HI-IgAP arise from structural features of the 
N-terminal chymotrypsin-like domain. Unlike most other proteins which have unstructured N-
termini, the HI-IgAP N-terminus is hydrophobic and buries itself into its chymotrypsin-like 
domain core, forming an essential part of the N-terminal fold (Fig. 2.2.1b).20 This hydrophobicity 
is not an issue during native expression as the proper N-terminus is revealed after signal peptide 
cleavage during secretion (Section 2.1). However when the enzyme is recombinantly expressed in 
the cytosol, the initiator methionine cannot be effectively removed, resulting in aggregation and 
the formation of insoluble inclusion bodies. Despite this, a miniscule amount of this recombinant 
HI-IgAP remains active and soluble due to basal activity of methionine aminopeptidase (MAP), 
an enzyme that cleaves N-terminal methionines.43 Armed with this knowledge, we developed our 
first-generation E. coli cytosolic expression system in hopes of getting around this N-terminal 




Figure 2.2.1 – The N-terminal protein-production problem. a) Comparing primary sequences of the mature wild-type (WT) and ∆27 HI-IgAP constructs: 
two N-terminal residues (red) were truncated to accommodate for the N-terminal formyl-methionine (blue) added during bacterial cytosolic expression; 
sequence was numbered based on UniProtKB entry #P45384. b) N-terminal fold of the WT HI-IgAP: the tightly packed N-terminus (A26 and L27) is 
highlighted. c) Hypothetical N-terminal fold of the mature ∆27 HI-IgAP: A26 and L27 were replaced by the N-terminal methionine; this methionine is 
theoretically well accommodated within the pocket created by removing these residues when solely considering the steric bulk of the surrounding crystal-
structure residues (d); the effect of this mutation on the protein’s other biophysical properties was not taken into consideration for the theoretical structure 
presented here.  
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2.3 – The First-Generation Cytosolic Expression System in Escherichia coli 
 The first-generation E. coli cytosolic system for producing recombinant HI-IgAP 
expressed the native non-codon-optimized HI-IgAP protease domain (ENA #AAA24966.1; 
residues 26-1006 based on UniProtKB entry #P45384) in BL21(DE3) cells. The gene was cloned 
into pET24b using the NdeI/XhoI sites. Various strategies to remove the initiator methionine 
during expression or purification were attempted by a previous Masters’ student in the lab: dual 
overexpression of MAP and HI-IgAP, post-expression treatment of MAP under denaturing 
conditions, cyanobromide to chemically remove the N-terminal methionine, and inclusion body 
refolding.44 Ultimately, no soluble or active protease was produced.44 
 I began considering other approaches to this problem. Instead of attempting to remove the 
initiator methionine, we designed a construct that would accommodate the methionine as part of 
its N-terminal fold. This new construct started two amino acids C-terminal to the mature N-
terminus (Fig. 2.2.1a), theoretically allowing the initiator methionine to take up the space freed up 
by removing these residues (Fig. 2.2.1c and 2.2.1d). Termed the ∆27 HI-IgAP, this construct was 
able to produce soluble (Fig. 2.3.1a) and active protease (Fig. 2.3.1b) with a two-day autoinduction 
expression at 20oC (Section 2.4).45 Even though this was an improvement over the previous 
system, only a small fraction of the total enzyme was soluble (Fig. 2.3.1a, red arrow).  
Further experimentation also suggested that the ∆27 HI-IgAP was incorrectly folded as 
attempts to optimize its purification failed due to reoccurring and unavoidable proteolytic 
degradation (Fig. 2.3.2a) and co-purifying contaminants (Fig. 2.3.2b), both of which could not be 
separated using ammonium sulfate precipitation, hydrophobic interaction, anion exchange, or size 
exclusion chromatography (data not shown). 
As this construct lacked the ability to produce enzyme with sufficient purity for 
biochemical analyses, I began investigating recombinant secretory expression systems as an 




Figure 2.3.1 – Solubility and activity of the ∆27 HI-IgAP construct. a) Solubility of the ∆27 HI-IgAP: the red arrow highlights the ∆27 HI-IgAP in the 
soluble fraction (C); only a tiny fraction of the total protein (B) is soluble; A is the uninduced lane, which is essentially identical to the soluble fraction of 
the wild type HI-IgAP. b) IgA1 cleavage assay: crudely purified and mostly degraded ∆27 HI-IgAP (lane D; full-length protein is the top band indicated 
by a red arrow) was incubated with IgA1 (E), showing activity by cleaving the heavy chain into two fragments, H1 and H2 (F); fragment and chain labels 
correspond to those described in Fig. 1.2.1. 
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Figure 2.3.2 – ∆27 HI-IgAP degradation products. a) Partially inhibiting degradation during purification: the major degradation product (blue arrow) 
was limited by adding 50 mM EDTA (C) to the protein sample (A); PMSF, a serine-protease inhibitor, did not prevent degradation (B). b) Final enzyme 
purity: even with the addition of EDTA throughout the entire purification, metalloprotease-associated degradation was still seen (blue arrow), albeit to a 
lesser degree than in panel a); other minor, but still significant, degradation products (red arrows) were also seen in the final product and could not be 
separated by simple chromatography. 
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2.4 – Expression and Purification Protocol for the ∆27 HI-IgAP 
A general overview for the production of ∆27 HI-IgAP is described below. The 
components of each buffer are listed in Table 2.4. All steps were done at 4oC unless otherwise 
specified. 
1. Grow an overnight BL21(DE3) E. coli starter containing the ∆27 expression construct at 
37oC from a glycerol stock. All media were supplemented with 50 µg/mL kanamycin. 
2. Add 50 mL starter into each liter of ZY-5052 media.45 Cells were incubated at 20oC for 
40-48 hours and were induced via autoinduction.45 
3. Cells were harvested using centrifugation for 10 minutes at 6,000xg. 
4. Cells were resolubilized in Resuspension Buffer and lysed via two passes through a 
FRENCH pressure cell (Thermo) at 1100 psi. 
5. The lysate was centrifuged for one hour at 12,000xg and the supernatant was incubated 
with EDTA-resistant Ni-Penta resin (Marvelgent) pre-equilibrated in Resuspension 
Buffer for 1 hour at 4oC. 
6. Ni-Penta resin was washed with 1 L Ni Wash Buffer followed by 1 L Resuspension 
Buffer. 
7. Ni-Penta resin was eluted with Ni Elution Buffer until A280 readings were below 0.05. 
8. Eluent was concentrated to less than 5 mL, using a 30 kDa MWCO centrifugal 
concentrator (Amicon), and loaded onto a manually packed Bio-Gel P-6DG desalting 
column (Bio-Rad) pre-equilibrated in Storage Buffer. 
9. The buffer-exchanged fractions were concentrated to less than 1 mL using a 30 kDa 
MWCO centrifugal concentrator and flash frozen in aliquots with liquid nitrogen. 
 
Buffer Name Components 
Resuspension 25 mM HEPES + 0.5 M NaCl + 5 mM imidazole + 50 mM EDTA 
Wash 25 mM HEPES + 0.1% (v/v) IgePal CA-630 + 5 mM imidazole + 50 mM EDTA 
Elution 25 mM HEPES + 0.5 M NaCl + 300 mM imidazole + 50 mM EDTA 
Storage 25 mM HEPES + 50 mM EDTA 
Table 2.4 – Purification buffers for the ∆27 HI-IgAP. HEPES, NaCl, EDTA, and imidazole were purchased from 
BioBasic and IgePal CA-630 from Sigma. All buffers have a pH of 7.5 at room temperature. All buffers were 
equilibrated to 4oC before use. 
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Section 3 – Developing the Pichia pastoris Secretory Expression System 
3.1 – Pichia pastoris as a Secretory Overexpression System 
 Pichia pastoris is a methylotrophic single-cellular yeast that has been optimized as a 
recombinant protein secretory system.46 Its relative ease of use, ability to form high-density cell 
cultures, and proven success in producing difficult proteins made P. pastoris a logical next step in 
the search for a viable method of HI-IgAP production.46,47 
A typical P. pastoris expression vector is shown in Fig. 3.1.1. Three main elements are of interest: 
1. Selectable marker – ADE2 gene 
P. pastoris strains used for protein expression are typically auxotrophic, meaning they 
have been genetically engineered to lack a particular or set of genes essential to de novo 
synthesis of a certain macromolecular nutrient.47 These auxotrophic strains are then 
transformed with expression vectors that complement the missing gene and grown on media 
lacking the auxotrophic nutrient to select for transformants.47 
Some auxotrophic P. pastoris strains lack ADE2, a gene which codes for an enzyme in 
the adenine biosynthetic pathway.48 Because of this knockout, untransformed ADE2-lacking 
cells accumulate a red metabolic adenine precursor when grown on adenine-lacking media.48 
This simplifies the process of identifying successful transformants as colonies containing the 
expression vector are theoretically colorless after transformation.48 
2. Induction method – AOX1 promoter 
In addition to preferentially using high-energy carbon sources such as glucose and 
glycerol, P. pastoris can use methanol, not only as a nutrient source but also to induce gene 
expression via the AOX1 promoter.46,47 The use of this promoter also enables glycerol-
mediated transcription repression, allowing for the growth of high-density cell cultures prior 
to induction using glycerol-amended media.47
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Figure 3.1.1 – Schematic of a typical P. pastoris expression vector. 
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3. Method of secretion – α-mating factor 
The Saccharomyces cerevisciae α-mating factor (α-MF) is the most common signal 
peptide used for recombinant protein secretion in P. pastoris.46,47 Expressing a protein of 
interest as a C-terminal fusion with an N-terminal α-MF allows the protein to shuttle into the 
endomembrane system for secretion.49 The α-MF is then cleaved in a two-step process, 
leaving behind no residual α-MF amino acids on the protein’s N-terminus.50 This property 
makes this particular signal peptide a great match for the recombinant expression of HI-IgAP 
(Section 2.2). 
 
3.2 – Vector Design and Transformation 
 The pPINK-HC vector (Invitrogen) was used as the backbone for the HI-IgAP P. pastoris 
expression vector. The recombinant construct consisted of an 85-residue N-terminal α-MF fused 
to residues 26-1006 of the HI-IgAP sequence (UniProtKB entry #P45384), followed by a C-
terminal hexahistidine tag (His tag). This sequence was codon-optimized for P. pastoris, 
synthesized, and cloned into the EcoRI/Acc65I sites of pPINK-HC using the services of GenScript 
USA. The codon-optimized gene sequence can be found in Appendix A and its corresponding 
primary sequence in Appendix B. 
 Invitrogen’s PichiaPink Strain 4 P. pastoris cells (genotype ade2- prb1- pep4-) were used 
for protein expression while E. coli DH5α cells (Thermo) were used for DNA maintenance. To 
prepare the plasmid, the vector was first linearized with EcoRI (Thermo) and dephosphorylated 
with alkaline phosphatase (FastAP; Thermo) in a one-pot reaction at 37oC for an hour. The 
enzymes were then heat inactivated at 95oC for 10 minutes. EcoRI was chosen as the linearization 
enzyme as it flanked the AOX1 promoter used for host plasmid integration. Competent cells were 
made and used according to Lin-Cereghino et al.’s condensed protocol.51 40 µL of fresh 
electrocompetent cells were electroporated with 100 ng linearized plasmid at 1.5 kV in a 0.2 cm 
MicroPulser electroporation cuvette (BioRad) using an Eppendorf 220V 940000017 
electroporator. Measured electroporation time constants were between 4 and 5 msec. 
Electroporated cells were then grown on adenine-lacking (PAD) plates (United States 
Biological) at 30oC for three days to develop colonies. Successful transformants were selected by 
color. If no negative transformants were identified, the plates were placed at 4oC until pigmentation 
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was seen. Positive transformants were further verified by colony PCR using universal 
AOX1/CYC1 primers, according to the protocol in the Invitrogen PichiaPink manual. Colonies 
verified by colony PCR were then grown to saturation in PAD media, diluted with 50% (v/v) 
glycerol to a final concentration of 25% (v/v) glycerol, and placed at -80oC for long-term storage. 
 
3.3 – Optimizing Protein Expression 
 PCR-verified transformants were then used in protein expression experiments as 
summarized in the Invitrogen PichiaPink manual. The following descriptions outline the main 
steps, their importance, and the parameters used in the first successful induction of HI-IgAP: 
1. Starter culture 
A starter culture is often used as the source of cells for initiating protein expression 
experiments as it allows for control over cell density, phase of cell growth, and consequently 
the growth rates prior to and during induction.52 To grow a HI-IgAP P. pastoris starter culture, 
a volume of PAD media was inoculated with a PCR-verified colony or glycerol stock. The 
volume of media inoculated varied depending on the desired volume of induced culture (see 
the “Log-phase growth and starvation” section below). The starter culture was then grown at 
30oC for three days in 1 L vented-cap baffled flasks (VWR) with shaking at 150 rpm. A 3:1 
headspace to media ratio was used to ensure sufficient aeration for optimal growth. 
2. Log-phase growth and starvation 
P. pastoris cell density was then increased by inoculating glycerol-amended nutrient-
rich media (BMGY; G for glycerol) with the starter culture at a 1:10 PAD inoculum to BMGY 
ratio. For example, 1 L of BMGY was inoculated with 100 mL of PAD starter culture, for a 
final total volume of 1.1 L. The glycerol was used as a high-energy supplement to facilitate 
high-density cell growth prior to protein induction.47 Cells in BMGY were grown at 30oC for 
18-24 hours in vented-cap baffled flasks, with a 3:1 headspace to media ratio and shaking at 
150 rpm. The media was then centrifuged for 10 minutes at 3,000xg to harvest the cells. The 
cell pellet was resuspended in BMGY without glycerol (BMWY; W for water) to starve the 
cells, allowing for the total consumption of residual glycerol, which would otherwise inhibit 





3. Methanol induction 
After an overnight growth, the media was centrifuged for 10 minutes at 3,000xg and 
resuspended in BMWY with 1% (v/v) methanol (BMMY; M for methanol) to begin induction. 
Cells in BMMY were grown at 30oC in 1 L vented-cap baffled flasks, with a 3:1 headspace 
to media ratio and vigorous shaking at 200 rpm. After induction, the cells were centrifuged 
for 10 minutes at 3,000xg and the supernatant was immediately used for purification. 
The first set of inductions took place over five days, with an additional daily dose of 100% 
methanol added to the culture to a final concentration of 1% (v/v) methanol. This was done under 
the assumption that all of the methanol was metabolized prior to the addition of new methanol, as 
methanol concentrations were not measured or controlled for during expression.  
Samples of media supernatant were taken on each day of induction to test for protein 
expression using trichloroacetic acid (TCA) precipitation53 and activity by monitoring IgA1 
cleavage using SDS-PAGE. Fig. 3.3.1 shows the promising results of HI-IgAP expression and 
activity after the first day of induction. HI-IgAP supernatant concentrations however, failed to rise 
after the first day (Fig. 3.3.2), suggesting that no new protease was produced past the initial burst 
of protein expression. The enzyme even seemed to degrade over the 5-day induction period, 
evident by the simultaneous disappearance of HI-IgAP band intensity and appearance of many 
degradation products (Fig. 3.3.2, red arrow). To prevent further degradation, the overnight growth 
in BMWY was removed as it did not impact protein induction or yield. As the glycerol carried 
over from BMGY into BMMY was still preferentially used over methanol, residual glycerol was 
still depleted to allow for methanol induction without switching to BMWY.54  
Ultimately, these attempts to increase the enzyme yield during induction were 
unsuccessful. Because I did not quantify cell culture densities or methanol concentrations over the 
course of the experiment, the reasons for these issues still remains inconclusive. However, the 




Figure 3.3.1 – Expression and activity of 
HI-IgAP produced from P. pastoris.   Lane 
A shows the activity of P. pastoris-
produced HI-IgAP via IgA1 cleavage. 5 µL 
of induced supernatant was incubated with 
15 µL of 0.3 mg/mL IgA1 (Athens 
Research; uncleaved in lane B) at 37oC for 
30 minutes. The IgA1 heavy chain (H) was 
fully cleaved into fragments H1 and H2 
(labelled according to Fig. 1.2.1). 1 mL of 
induced supernatant was TCA precipitated 
and loaded into lane C. The red arrow 
highlights the HI-IgAP band. 
Figure 3.3.2 – Time course of the P. pastoris HI-IgAP induction profile. 1 mL of supernatant was TCA precipitated 
on each day of the induction period, with lanes B to F corresponding to days 1 to 5 post-induction. HI-IgAP activity on 
days 4 (E’) and 5 (F’) were analyzed as previously described. Lane A is the uncleaved IgA1 negative control. The red 
arrow highlights one of the many degradation products that appeared in significant amounts starting on day 3 (lane D). 
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 Instead of attempting to optimize enzyme yield during expression, my focus shifted 
towards finding ways to increase yield by changing conditions prior to induction. As HI-IgAP 
expression seemed to occur all-at-once, I hypothesized that further increasing the cell density past 
a one-day BMGY growth may improve yields as a result of the larger cell mass available for 
enzyme production. This did not hold true as enzyme yield significantly decreased when cells were 
induced after two or more days of BMGY growth (Fig. 3.3.3, left). This was possibly due to the 
cells no longer being in the exponential phase of growth optimal for protein expression.46,50 
Changing the methanol concentration used during induction showed a greater effect on yield than 
BMGY growth time (Fig. 3.3.3, right). However, differences in yield between the first (Fig. 3.3.2) 
and this (Fig. 3.3.3, 2.0% lane) expression were negligible. Unfortunately, since the culture’s 
growth density and cell viability were not measured, it was hard to conclude whether this lack of 
expression was due to changes in growth phase or because of other confounding variables.  
 Despite my attempts at optimizing expression, little to no increase in yield was seen. A 
more in-depth study of the factors underlying expression therefore needs to be done to fully 
understand the nuances of this P. pastoris system.
Figure 3.3.3 – Optimizing P. pastoris HI-IgAP production.  Cells were grown under different expression 
conditions to optimize for HI-IgAP yield. This gel shows the TCA-precipitated profile of 1 mL supernatant 
collected one day after induction. The best cell density for expression, out of the experimental conditions, 
was obtained after only one day of BMGY growth. The best methanol (MeOH) concentration for a one-day 
BMGY growth, out of the experimental conditions, was around 2.0% methanol. 
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3.4 – Optimizing Protein Purification 
Before the purification of HI-IgAP from P. pastoris cell culture supernatant is described, 
an important aspect in this section’s SDS-PAGE gels must first be addressed: the apparent 
molecular weight of the HI-IgAP is shown to shift, ranging from just under 100 kDa up to 130 
kDa. This is seen between enzyme produced from the same cell stock but in different expression 
batches. The cause of this inconsistency was never resolved, as mass spectrometry was never 
performed on the shifting bands. It is therefore assumed that the predominant band of the 
expression profile represented the HI-IgAP. As fractions containing this band always showed 
activity, and those lacking this band showed no activity, it was a reasonable assumption to make. 
Each purification attempt used a minimum of 2 L culture to compensate for the poor yield 
of each expression batch (Fig. 3.3.1). Affinity chromatography was therefore used as the go-to 
purification method to take advantage of the construct’s C-terminal His tag. Our lab has previous 
experience using nickel-chelated immobilized metal affinity chromatography (Ni-IMAC) to 
capture HI-IgAP secreted from H. influenzae.20 As such, we knew that the components in sugar-
rich media, including those typically used to grow H. influenzae and P. pastoris, easily 
outcompeted HI-IgAP for affinity resin binding. An excessively large amount of Ni-IMAC resin 
was therefore used to bind the enzyme directly from the supernatant. 100 mL of settled Ni-IMAC 
resin (Ni-NTA; Molecular Cloning Laboratories) equilibrated in 25 mM HEPES (BioShop), pH 
7.5 was incubated with the supernatant for an hour at 4oC. The resin was then washed with 2 L 
HEPES buffer before being eluted with a buffer containing 25 mM HEPES and 0.3 M imidazole, 
pH 7.5.  
Due to non-specific binding of unidentified contaminants within the media, the Ni-IMAC 
eluent had a dark yellow to deep brown hue. Adding 0.5 to 1 M NaCl to the wash buffer did not 
noticeably change this discoloration. Spectrophotometric methods (i.e. A280 measurements) thus 
could not be used to determine the protein concentration as the media had partial absorbance at 
280 nm. Instead, concentrations were semi-quantitatively assessed by comparing SDS-PAGE band 
intensities to other bands with known concentrations. 
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Despite a C-terminal His tag present in the construct, the Ni-IMAC eluent contained no 
enzyme as the eluent showed no activity and HI-IgAP was not seen in its TCA precipitation (Fig. 
3.4.1, lane A). The opposite was true for the flow through (Fig. 3.4.1, lane B). I hypothesized that 
this lack of binding was due to the relatively low pH of the media supernatant. As BMMY is 
heavily buffered at pH 6.0 for optimal growth, the His tag’s imidazole groups were likely only 
semi-deprotonated as their approximate pKa of 6.6 comes too close to this pH.55 Unfortunately the 
enzyme still did not bind even after the supernatant pH was raised to 8.0 using 1 M pH 12.0 K3PO4 
post-expression. An anti-His-tag dot blot done on the induced supernatant and cell pellet (Fig. 
3.4.1, right) suggested that the secreted HI-IgAP did not contain a His tag despite it being part of 
the expression construct. This may have been due to non-specific autoproteolysis of the C-terminus 
after secretion, which is known to occur in the native H. influenzae system.20 
A strong anion-exchange resin (Q Sepharose; GE) was used as an alternative to Ni-IMAC. 
This was used to concentrate the enzyme for downstream purification while removing problematic 
media components. Q Sepharose’s much higher binding capacity, relative to Ni-IMAC, also 
allowed the enzyme to bind even with non-specific interactions with the media. Since BMMY has 
high ionic strength, ammonium sulfate precipitation was first used to lower the ion concentration 
by precipitating and resuspending the enzyme in no-salt buffer. 75 g of ammonium sulfate was 
added to every 100 mL of BMMY supernatant. The mixture was stirred at 4oC for at least an hour 
and formed an opaque solution. The precipitated slurry was centrifuged at 10,000xg and 4oC for 
an hour and the supernatant was discarded. The pellet was dissolved in and diluted to 2L with 25 
mM Tris base (BioBasic), pH 7.5 and incubated with 200 mL settled Q Sepharose resin 
equilibrated in the same buffer. Q Sepharose resin was then washed with 2 L Tris buffer and eluted 
Figure 3.4.1 – Ni-IMAC eluent 
and flow-through profiles. This 
gel shows the non-specific binding 
of high-molecular-weight 
contaminants (A) to the Ni-IMAC 
resin. Lane B is the 1 mL TCA-
precipitation of the flow through, 
which contained all of the secreted 
HI-IgAP. The anti-His tag dot blot 
(right) shown is an overlay of the 
samples’ position and 
corresponding fluorescence, 
highlighting the lack of a His-tag 
on the secreted HI-IgAP. 
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with 25 mM Tris, pH 7.5 supplemented with 2 M NaCl. Although the eluent (Fig. 3.4.2, lane A) 
still retained its strong yellow color, most of the color was removed through this process. The Q 
Sepharose eluent still would not bind to Ni-IMAC resin despite removing most of the 
contaminating media components, reinforcing the idea that the His tag was post-translationally 
removed during expression. 
At this point, the approximate yield of a 2 L induction was less than a milligram of enzyme. 
As any additional steps led to a significant loss in yield, I decided to forego further purification 
until the issue of yield could be resolved. Thus, the anion-exchange eluent was immediately 
concentrated using a 30 kDa centrifugal concentrator (Amicon) to under 1 mL and flash frozen 
with liquid nitrogen. The concentrated protein (Fig. 3.4.2, lane B) still retained a strong yellow 
color despite efforts to de-color the solution with prolonged and successive dialyses. 
Figure 3.4.2 – Q Sepharose elution profile. The protein profile of 1 mL TCA-precipitated 
Q Sepharose eluent is shown in lane A and is similar to that shown in Fig. 3.3.4. The final 
purity of the enzyme after concentration is shown in lane B. 
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3.5 – Finalized P. pastoris Protein Production Protocol   
My general P. pastoris expression and purification workflow is summarized below. All 
pH values were measured at room temperature. All cultures were grown in 1 L baffled flasks 
with a 3:1 headspace to media ratio. Flasks were shaken at 150 rpm unless otherwise specified. 
1. Grow a PAD starter culture from a glycerol stock or colony for three days at 30oC.  
2. Inoculate BMGY at a 1:10 PAD inoculum to BMGY ratio and grow overnight at 30oC. 
3. Cells were centrifuged at 3,000xg for 15 minutes and transferred to BMMY containing 
2% (v/v) methanol. Cells were grown overnight at 30oC with shaking at 200 rpm. 
4. The supernatant was harvested using centrifugation at 3,000xg for 15 minutes and the cell 
pellet discarded. 
5. 75 g of ammonium sulfate was added to every 100 mL supernatant. The mixture was 
stirred at 4oC until the solution turned opaque. 
6. The precipitated enzyme was harvested by centrifugation at 10,000xg for 1 hour at 4oC. 
7. The pellet was dissolved and incubated in 100 mL Q Sepharose (GE) resin pre-
equilibrated in 25 mM Tris (BioBasic), pH 7.5. 
8. The Q Sepharose resin was washed with 1 L 25 mM Tris, pH 7.5 and eluted with 1 L 25 
mM Tris, pH 7.5 supplemented with 1 M NaCl. 
9. Eluent was concentrated to less than 5 mL, using 30 kDa MWCO stirred-cell and 
centrifugal concentrators (Amicon), and loaded onto a manually packed Bio-Gel P-6DG 
desalting column (Bio-Rad) pre-equilibrated in 25 mM HEPES, pH 7.5. 
10. The buffer-exchanged fractions were concentrated to less than 1 mL using a 30 kDa 
MWCO centrifugal concentrator and flash frozen in aliquots with liquid nitrogen. 
The final yield was approximately 0.9 mg enzyme from a 2 L expression, as semi-
quantitatively estimated by SDS-PAGE. Based on inspection by eye, the final purified enzyme 





3.6 – Shortcomings and Next Steps 
There are several shortcomings to this system. Most notably, its low yield coupled with co-
purification of media components made the already lengthy purification even more difficult and 
resource-intensive. The lack of a His tag suggested that the C-terminus can be re-engineered to 
prevent autoproteolysis, potentially mitigating some loss during purification. Yields could also be 
improved by using a bioreactor, which optimizes oxygen and methanol concentrations in real time 
to form high-cell-density cultures that express better than shaking vented-cap flasks.47  
The fact that expression occurred as a one-time response to methanol suggested that the 
vector failed to integrate into the P. pastoris genome, as it should have, and thus was discarded 
mid-induction.54,56 When the cells were transferred from PAD into BMGY media, the auxotrophic 
pressure of PAD media was removed as BMGY is nutrient-rich. Without any selective pressure, 
the plasmid was readily discarded to lessen the energetic cost associated with its expression.54 
Linearizing the expression vector within the TRP2 gene may have been a better alternative to host 
integration over linearizing the AOX1 promoter. Positive transformants can also be tested for 
successful genomic integration via PCR. Furthermore, the number of copies integrated should be 




Section 4 – Developing the Second-Generation E. coli Cytosolic Expression System 
 I was fortunate to have an opportunity to intern in our collaborator’s lab (Dr. Elan Z. 
Eisenmesser; University of Colorado, Denver, Anschutz Medical Campus) through our existing 
partnership on the IgAP project. His lab uses nuclear magnetic resonance (NMR) to look at the 
dynamics and structure-function relationships of immune-system proteins. Because of the notable 
differences between how they use NMR and how our lab uses X-ray crystallography to answer 
similar biochemical questions, I was able to learn a complimentary set of techniques that sparked 
the idea for a second-generation E. coli HI-IgAP production system. Particularly, their methods of 
denatured purification, used as part of their NMR toolkit, was something that our lab never had 
success with and therefore rarely used. Although we attempted denaturing and refolding 
techniques during the development of our first-generation E. coli system (Section 2.3),44 my 
internship experiences showed me that we needed to make major adjustments to our previous 
approach before we even had a chance at success. 
 
4.1 – Alternative Approach to the E. coli Cytosolic Expression System 
My new experiences with protein denaturation made me reconsider our first-generation E. 
coli system, precisely because the HI-IgAP produced almost always formed insoluble inclusion 
bodies (Section 2.2 and 2.3). Although these aggregates could not be previously resolubilized,44 
their insolubility would provide several advantages over traditional methods of soluble 
purification, given that a feasible method of resolubilizing and refolding could be developed.  
Insolubility not only protected the enzyme from proteolysis during expression, as most molecules 
in inclusion bodies are not accessible to solvent,57 but also allowed for the separation of a vast 
majority of soluble contaminants by isolating and purifying just the insoluble cell fraction. The 
success of this new inclusion-body purification was contingent on two criteria, both of which were 
lacking in our first-generation approach. One, all exogenous N-terminal residues must be removed 
before the enzyme is refolded (Section 2.2). And two, the refolding process must be altered to slow 
the rate of precipitation and aggregation to allow for proper protein folding. 
The solution to the first criterion involved modifying the first-generation expression 
construct to better suit a denatured approach. This new construct (Fig. 4.1.1; sequences in 
Appendices C and D) comprised of a small ubiquitin-like modifier (SUMO; UniProtKB entry 
#A6ZZ98) N-terminally fused to the HI-IgAP protease domain. After cleavage with ubiquitin-like-
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specific protease 1 (ULP1; UniProtKB entry #Q02724), which recognizes the SUMO tertiary 
structure and cleaves C-terminal to a double-glycine motif (Fig. 4.1.1),58 no SUMO residues are 
left behind. Without any exogenous N-terminal residues, the protease is now able to properly fold. 
This is similar to the N-terminal processing involved in the P. pastoris α-MF secretory pathway 
(Section 3.1). The plasmid expressing ULP1 was a gift from Dr. Christopher Lima (Sloan 
Kettering Institute) and its purification protocol is described in Appendix E. 
4.2 – Vector Design 
The second-generation E. coli expression vector (Fig. 4.1.1; SUMO-HI-IgAP) was created 
in two steps. First, the sequence coding for untagged SUMO was cloned upstream of the HI-IgAP 
gene. The second round of cloning simultaneously modified the vector in two ways: it ensured that 
the HI-IgAP sequence after ULP1 cleavage started at A26, and it moved the His tag from the HI-
IgAP C-terminus to the SUMO N-terminus. The location of the His tag was switched to allow for 
the separation of His-tagged contaminants from untagged and cleaved HI-IgAP (Fig. 4.3.1). 
The first-generation ∆27 E. coli expression vector (Section 2.3) was used as the starting 
point for modifications. To prevent complications with autoproteolysis,20 the inactive mutant (∆27 
S288A) was used. The Takara Bio In-Fusion Cloning kit was used in both cloning steps to simplify 
Gibson assembly methods. Hence, all primers contained a 20 to 30 bp 5’ overhang engineered to 
be complimentary to the sequences flanking the insertion site (Table 4.2). For the first stage of 
cloning, the SUMO gene was PCR amplified from an expression vector containing a SUMO-fused 
protein. The PCR product was then gel purified (Qiagen) and cloned into the NdeI site of the ∆27 
S288A pET24b vector using the In-Fusion kit. 
Figure 4.1.1 – Schematic representation of the second-generation E. coli HI-IgAP construct. The 
primary sequence surrounding the ULP1 cleavage site (“|”) is shown. After cleavage, the primary sequence 




As the ∆27 S288A construct was used as the template, residues A27 and L28 were missing 
and had to be added to the sequence after the ULP1 cleavage site (Fig. 4.1.1). This was done with 
two consecutive PCR reactions. The first reaction amplified a DNA fragment which coded for an 
N-terminal His tag, SUMO, and part of the HI-IgAP sequence containing A27 and L28. This large 
fragment was used as the forward primer for the subsequent PCR reaction, where the rest of the 
HI-IgAP sequence, excluding the C-terminal His tag, was amplified. This was then inserted into 
the NdeI site of a pET21 empty vector (Novagen). BL21(DE3) E. coli cells were transformed with 
the expression vector and subsequently stored in 25% (v/v) glycerol for future expressions. The 
construct sequence was verified after each cloning step (Integrated DNA Technologies). 
 
4.3 – Overview of the Second-Generation Cytosolic Production System in E. coli 
A general overview of the preliminary protein production protocol is described below and 
summarized in Fig. 4.3.1. The components of each preliminary buffer are listed in Table 4.4, 
column A. All steps were done at 4oC, unless otherwise specified. 
1. 4L culture was grown and induced in ZY-5052 media via autoinduction at 20oC for 40-48 
hours.45 All media were supplemented with 50 µg/mL ampicillin. 
2. Cells were harvested using centrifugation for 10 minutes at 6,000xg. 
3. Cells were resolubilized in 100 mL Resuspension Buffer, lysed via two passes through a 
FRENCH pressure cell (Thermo) at 1100 psi, and centrifuged for an hour at 12,000xg. 
4. The supernatant was discarded and the pellet was fully dissolved in 50 mL Denaturing 
Buffer. 
Sequence (5’ to 3’) Type Function 
ATT TTG TTT AAC TTT AAG AAG GAG ATA TAC 
ATA TGT CGG ACT CAG AAG TCA ATG AAG forward To amplify the SUMO gene for Gibson assembly into the NdeI site upstream of 
the ∆27 HI-IgAP in pET24b GAT AAT CCA CAT CGT CTC TCA CCA TAT GAC CTC CAA TCT GTT CGC GGT G reverse 
CTT TAA GAA GGA GAT ATA CAT ATG ATG GGT 
CAT CAC CAT CAT CAT CAC GGG TCG GAC forward To generate a large forward primer which includes the A26, L27, and N-
terminal His tag GAT AAT CCA CAT CGT CTC TCA CTA AGG CAC CTC CAA TCT GTT C reverse 
The ~1,100 bp sequence generated from the PCR 
amplification of above forward 
To amplify the SUMO-HI-IgAP gene 
with an N-terminal His tag for Gibson 
assembly into the NdeI site of an empty 
pET21 vector 
CAC CAG TCA TGC TAG CCA TAT GTT AAG GTG 
TTG TGA TAT TTG TCG TAT CGA CAG TTT G reverse 
Table 4.2 – Primers used to create the second-generation E. coli expression vector. NdeI was used to linearize all 
vectors. Its restriction site is highlighted in bold. Primers were ordered dry from Integrated DNA Technologies. 
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5. The protein was incubated with 10 mL settled Ni-IMAC resin (NiNTA; Molecular 
Cloning Lab), pre-equilibrated in Denaturing Buffer, for an hour with agitation. 
6. The Ni-IMAC resin was washed with 1 L Wash Buffer and eluted with Elution Buffer 
until A280 readings were under 0.05. 
7. Eluent was dialyzed overnight with 14 kDa MWCO dialysis tubes (Aldon Corporation) 
into Arginine Buffer with a 10-fold-excess dialysis volume. 
8. The dialysis buffer was changed to Refold Buffer and the protein was dialyzed overnight. 
9. The dialyzed solution was incubated with 3 mg homemade ULP1 for three hours at room 
temperature on a rocking shaker. Precipitated protein was removed by centrifugation at 
12,000xg for 15 minutes.  
10. 50 mL of Ni-IMAC resin, equilibrated in Storage Buffer, was incubated with the ULP1-
treated protein for an hour. 
11. The resin was rinsed with two column volumes of Storage Buffer and the flow through 
and rinse solution were concentrated with 30 kDa stirred-cell and centrifugal 
concentrators (Amicon) to less than 5 mL. 
12. The concentrated protein was injected onto a Sephacryl S-200 HR (GE) size-exclusion 
chromatography (SEC) column, equilibrated in Storage Buffer. The column was operated 
by a Biologic DuoFlow FPLC (Bio-Rad) and ran at 0.5 mL/min. 
13. Fractions containing non-aggregated protein were concentrated using a 30 kDa 
centrifugal concentrator to less than 1 mL and frozen with liquid nitrogen. 
Refolding protocols commonly use a one-step dialysis to transition the protein from its 
unfolded state, in high concentrations of denaturant (e.g. guanidinium hydrochloride; GdnHCl), to 
a solution with no denaturant.59 Through this process, the protein ideally follows a 
thermodynamically favorable path towards a proper fold.59 This was how we attempted our first 
HI-IgAP refold (Section 2.3).44 However, this one-step refold is often unsuccessful because of a 
problem arising from the kinetic relationship between protein precipitation and refolding. There 
are two paths available to the denatured protein when denaturants are removed: one towards the 
desired folded state, assuming it can occur under the refolding conditions, and the other towards 
aggregation.60 Although both paths are available, the rate of aggregation is typically much higher 
than that of folding due to the greater frequency of unwanted protein-protein interactions that occur 
when core side chains are exposed.60 This is exacerbated by the abnormally high concentrations 
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of unfolded protein during the refold, compared to that of the natural folding environment.59 
Overall, this leads to the vast majority of protein precipitating instead of refolding. 
A potential solution is the addition of an intermediate refolding step to bridge the gap 
between the totally denatured and natively folded states. The HI-IgAP was therefore dialyzed from 
5 M GdnHCl first into 1 M arginine before subsequently dialyzed into a soluble buffer. Rather 
than acting as a molecular chaperone, arginine works as a molecular crowder, simulating the 
packed cellular environment in which protein folding typically takes place.60 This reduces the 
frequency and scale of unwanted protein-protein interactions, slowing the rate of precipitation 
enough to allow for protein folding to take place.60 Since HI-IgAP naturally folds after passing 
through the outer membrane (Section 2.1), it stood to reason that it would do the same in vitro. We 
were lucky that this was the case.  
Figure 4.3.1 – 





A typical denatured HI-IgAP purification is shown in Fig. 4.3.2. Samples with GdnHCl or 
arginine were prepared using ethanol precipitation: 1 mL of -80oC 100% ethanol was added to 50 
µL of sample and set to precipitate for an hour at -80oC. The mixture was centrifuged at 14,000xg 
for a minute, the supernatant discarded, and the pellet was washed in -20oC 70% (v/v) ethanol. The 
sample was centrifuged at 14,000xg for a minute, the supernatant discarded, and residual ethanol 
was removed by heating the sample at 80oC for several minutes. SDS loading dye and water was 
added to a total volume of 200 µL. The sample was heated at 80oC until the pellet was completely 
dissolved. 10 µL of sample was added to each gel lane. 
  
Figure 4.3.2 – Preliminary denatured HI-IgAP purification. With an N-terminal SUMO (~12 kDa), the new HI-
IgAP construct was ~120 kDa. Lane identities include: (A) total induced; (B) uninduced; (C) 1st Ni-IMAC eluent; 




4.4 – Optimizing Protein Expression and Purification  
 This section focuses on optimizing several key steps of the purification (Section 4.3). Each 
key step will be detailed within its own subsection. All of the buffers referenced below have been 
amended to reflect this optimization. Their components are listed in Table 4.4, column B. 
Protein Expression (Step #1) 
 Autoinduction was initially used to express this second-generation construct based on our 
previous success using it over IPTG in our first-generation system (Section 2.3). However, it 
turned out that the total amount of protein produced per volume of cell culture was almost identical 
between a two-day autoinduction at 20oC and a three-hour induction with 1 mM IPTG at 37oC. As 
such, there was no reason to continue using autoinductive methods due to its longer growth time 
and higher contaminant background. Furthermore, a higher incubation temperature also facilitated 
inclusion body formation, allowing for a greater level of protection against proteolysis during 
expression compared to lower temperatures.57 That said, incubation temperatures beyond 37oC, 







Preliminary (A) Optimized (B) 
Resuspension 25 mM HEPES 
Denaturing 50 mM sodium phosphate + 0.5 M NaCl + 10 mM imidazole + 5 M GdnHCl 
Wash Same as Denaturing Buffer Same as Denaturing Buffer but with 1% (v/v) IgePal CA-630 and no NaCl 
Elution Same as Denaturing Buffer but with 300 mM imidazole 
Arginine 100 mM Tris + 0.3 M NaCl + 1 M arginine 100 mM Tris + 0.3 M NaCl                               + 1 M arginine + 50 mM EDTA 
Refold 50 mM sodium phosphate + 0.15 M NaCl 
(Refold A) 50 mM sodium phosphate + 0.15 M 
NaCl + 0.3M GdnHCl + 50 mM EDTA 
(Refold B) 25 mM HEPES + 0.3M NaCl 
Storage 25 mM HEPES 
Table 4.4 – Denatured HI-IgAP purification buffers. HEPES, Na2HPO4, NaCl, imidazole, and disodium EDTA 
dihydrate were purchased from BioBasic, GdnHCl and arginine from ChemImpex, and IgePal CA-630 from Sigma. 
All buffers have a pH of 7.5 at room temperature. All buffers were equilibrated to 4oC before use. 
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Lysis (Steps #3 and 4) 
 Because SUMO-HI-IgAP is highly insoluble, the lysate pellet can be resuspended in a non-
denaturing buffer to remove residual soluble contaminants. Thus after centrifuging the initial 
lysate, the pellet was resuspended in Resuspension Buffer for a second time and passed through 
the FRENCH press system to maximally solubilize contaminants. This mixture was centrifuged at 
12,000xg and the supernatant was discarded. After the second centrifugation, there was a 
noticeable decrease in pellet size with no noticeable loss in IgAP. This pellet was then dissolved 
in Denaturing Buffer. 
First Ni-IMAC (Step #5 and 6) 
 A large proportion of protein did not bind to the first denatured Ni-IMAC, even though the 
solution loaded onto the resin was homogenous and free of visible particles. Binding was 
significantly improved when the solution was first vigorously sonicated to break up and fully 
denature non-visible aggregates. This resulted in a 10-fold increase in Ni-IMAC binding. 
 Because of the Ni-IMAC was done under denaturing conditions, the resin washes could be 
modified to higher stringency to remove sticky contaminants that were bound through non-specific 
electrostatic and hydrophobic interactions. Those bound with weak electrostatic interactions were 
removed using the same high-salt Denaturing Buffer. Hydrophobically interacting contaminants 
were removed using the new Wash Buffer, which contained a high concentration of non-ionic 
detergent and no additional salt. Ten column volumes of Denaturing Buffer were used to remove 
residual detergent, and the protein was eluted using the same Elution Buffer. 
Two-Step Refold (Steps #7 and 8) 
 Proteins undergoing refolding are particularly susceptible to proteolysis, particularly if 
other proteases fold faster than the protein of interest.57 Thus, protease inhibitors are often added 
in the refold buffers to reduce degradation.57 Initial refolding of the HI-IgAP displayed a consistent 
set of degradation products that would appear and increase in intensity throughout the refold (Fig. 
4.4.1, red arrow). Upon addition of a metalloprotease inhibitor, EDTA, to the Arginine and Refold 
Buffers, degradation no longer occurred. 
 Even with an intermediate arginine step, a large proportion of the total enzyme precipitated 
when it was dialyzed from the Arginine Buffer into the preliminary Refold Buffer. This was 
addressed in two ways. The Ni-IMAC eluent was first diluted three-or-more fold with Denaturing 
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Buffer to lower the protein concentration and hence the rate of aggregation.60 For example, a 
typical volume of 40 mL Ni-IMAC eluent was diluted to 200 mL for dialysis. A third refolding 

















ULP1 Cleavage (Step #9) 
In addition to protein loss during refolding, heavy precipitation was seen after ULP1 
treatment. As cleavage of SUMO is necessary for proper folding, it is not surprising that 
aggregation was especially prevalent during this step. To increase the solubility and assist in the 
folding of cleaved HI-IgAP, ULP1 cleavage was tested under various mildly denaturing 
conditions. The condition which provided the best solubility with the least amount of degradation 
was 0.3 M GdnHCl (Fig. 4.4.2, lanes C and C’). Unwanted degradation occurred when SUMO 
was cleaved under urea (Fig. 4.4.2, red arrow). Therefore, Ni-IMAC eluent was first dialyzed 
into Arginine Buffer then into buffer with 0.3 M GdnHCl (Refold A Buffer), cleaved with ULP1 
at room temperature, then dialyzed once more time into the Refold B Buffer with no denaturant. 
Figure 4.4.1 – Effect of EDTA on 
HI-IgAP refolding. This figure 
shows the effect of EDTA on 
degradation during refolding. Eluent 
from the denatured Ni-IMAC was 
dialyzed against Arginine and Refold 
Buffer with (lane B) and without 
EDTA (lane A).  The red arrow 
highlights degradation products that 
are not present when the refold is 
done under EDTA. 
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The tradeoff of cleaving SUMO under semi-denaturing conditions was the inevitable 
slowing of ULP1 activity.58 Monitoring the reaction over several hours at room temperature 
showed that full SUMO cleavage could not be achieved using only one three-milligram dose of 
ULP1 (Fig. 4.4.3). A minimum of two doses and overnight incubation were necessary for near-
complete cleavage. As HI-IgAP seemed to be stable at room temperature, given the lack of 
degradation products in Fig. 4.4.3, lane E, further optimizing cleavage conditions will only reduce 
the reaction time and amount of ULP1 used but is not essential to obtaining pure HI-IgAP. 
Figure 4.4.2 – Effect of mild denaturant on ULP1 cleavage. Ni-IMAC eluent was first dialyzed into Arginine 
Buffer then into the following buffers. All buffers contained 50 mM phosphate, pH 7.5, 150 mM NaCl, and a 
mild denaturant. All lanes with prime labels (’) represent post-ULP1-treated protein. Noticeable degradation 
products (red arrows) were seen in buffers containing urea. The blue arrow indicates the cleaved SUMO. The 
identities of the mild denaturants for each lane are: (A) Protein in Arginine Buffer; (B) No denaturant; (C) 0.3 M 












Size-Exclusion Chromatography (Step #12)  
 Using size-exclusion chromatography (SEC) to separate HI-IgAP aggregates from 
correctly folded protein was very successful (Fig. 4.4.4 and 4.4.5). HI-IgAP that was uncleaved, 
and therefore improperly folded (Fig. 4.4.4, red arrow), formed large aggregates by associating 
with itself and other properly folded proteins. These complexes eluted at the void volume and were 
able to be separated from properly folded and non-aggregated HI-IgAP (Fig. 4.4.5). However, 
initial SEC runs showed that a large proportion of the properly folded protein was being pulled 
into the void volume by uncleaved HI-IgAP (Fig. 4.4.4 and 4.4.5a). When the protein was 
extensively dialyzed into a no-salt SEC buffer before running the column, there was a notable shift 
towards a non-aggregated state (Fig. 4.4.5b). At the moment, it is unclear whether this shift was 
due to changes in ionic strength or because of the prolonged dialysis. Hence, more experimentation 
needs to be done to optimize this purification step. 
  
Figure 4.4.3 – Time course of ULP1 
cleavage in Refold A Buffer. This 
figure shows the progress of SUMO 
cleavage over several hours. 3 mg ULP1 
(one dose) was added to the protein (A) 
at room temperature. Samples were 
taken at 1 (B), 2 (C), and 3 (D) hours 
post-incubation. Lane E represents the 
overnight cleavage after 3 more 





Figure 4.4.4 – S200 SEC 
fractions. This figure 
highlights the pull-down 
effect of aggregate-inducing 
uncleaved HI-IgAP (red 
arrow) on a S200 SEC 
column. The gel lanes span 
the two peaks of the Fig. 
4.4.5a trace, where the void 
peak is represented in the 
left-most three lanes and the 
elution peak is represented 






Figure 4.4.5 – S200 
aggregation.  This figure shows 
the effect of salt in the injected 
protein buffer on the relative 
intensities of the void and 
elution peaks. Both SEC runs 
were equilibrated in 25 mM 
HEPES, pH 7.5 and run at 0.5 
mL/min. The different absolute 
void and elution volumes 
between the two runs were due 
to different bed volumes.  
a) Protein was injected in buffer 
containing 0.15 M NaCl 
 
b) Protein was injected with in 
buffer containing no salt, which 
was obtained by using 




4.5 – Finalized SUMO-HI-IgAP E. coli Protein Production Protocol 
My second-generation denatured HI-IgAP workflow is summarized below. A typical 
expression and purification yields 2 mg HI-IgAP per liter of E. coli culture with a purity greater 
than 99%, as determined by eye (Fig. 4.5.1). All of the buffers below refer to the optimized buffers 
in Table 4.4, column B. Steps were performed at 4oC, unless otherwise specified. 
1. Grow an overnight SUMO-HI-IgAP BL21(DE3) E. coli starter at 37oC from a glycerol 
stock. All media were supplemented with 50 µg/mL ampicillin. 
2. Inoculate 50 mL starter into each liter of LB media. 
3. Grow LB at 37oC until an OD600 of 0.6-0.9 and induce at 37oC with 1 mM IPTG for three 
hours. A typical purification involves using cells from 6-8 L E. coli culture. 
4. Harvest the cells by centrifugation at 6,000xg for 10 minutes. 
5. Resuspend the pellet in 100 mL Resuspension Buffer until mix until homogenous. 
6. Lyse the cells via two passes through a FRENCH pressure cell (Thermo) at 1100 psi. 
7. Centrifuge the lysate for one hour at 12,000xg, discard the supernatant, and resuspend the 
lysate pellet in 100 mL Resuspension Buffer and mix until homogenous. 
8. Repeat Step #6. 
9. Centrifuge the second lysate for one hour at 12,000xg and discard the supernatant. 
10. The pellet was vigorously sonicated on ice in 50 mL Denaturing Buffer using a Qsonica 
Q500 sonicator and 1/2”-diameter tip (Qsonica) at 60% maximum amplitude with a 20/40 
sec on/off cycle. The total sonication time was 10 minutes. 
11. The sonicated mixture was loaded onto a Bio-Rad DynaLoop 90 injection loop pre-
equilibrated in Denaturing Buffer. The dynamic loop was then hooked up in parallel to a 
Biologic DuoFlow FPLC (Bio-Rad) and was injected onto 20 mL Ni-IMAC resin 
(NiNTA; Molecular Cloning Lab) for denatured purification. The resin was extensively 
washed with 1 L Wash Buffer followed by 1 L Denaturing Buffer to remove residual 
detergent. SUMO-HI-IgAP was eluted isocratically with Elution Buffer until A280 
readings were below 0.05. 
12. Eluent was diluted three-fold using Denaturing Buffer and dialyzed overnight in 14 kDa 
MWCO dialysis tubes (Aldon Corporation) against 10-fold-excess Arginine Buffer. The 
protein was further dialyzed overnight into 10-fold-excess Refold A Buffer. 
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13. The dialyzed protein solution was incubated with homemade ULP1 at room temperature 
overnight for SUMO cleavage on a bench-top rocker. 3 mg ULP1 was added at the start 
of cleavage and dosed in every three hours, with a minimum of one extra dose. 
14. Precipitate was removed by centrifugation at 12,000xg for 15 minutes. 
15. Cleaved HI-IgAP was dialyzed against a 10-fold excess of Refold B Buffer overnight. 
16. Protein was incubated with 100 mL Ni-IMAC resin equilibrated in Refold B Buffer for 
an hour. The resin was rinsed with 500 mL Refold B Buffer.  
17. The flow through and rinse solutions were concentrated to less than 10 mL using a 30 
kDa MWCO stirred-cell concentrator (Amicon).  
18. The protein was extensively buffer exchanged into Storage Buffer using the stirred-cell 
concentrator with repeated dilutions and concentrations, overnight dialysis, or a desalting 
column (Bio-Gel P-6DG; Bio-Rad). 
19. The protein was concentrated to less than 5 mL using a 30 kDa MWCO centrifugal 
concentrator (Amicon) and injected onto a manually packed S200 HR SEC column (GE) 
equilibrated in Storage Buffer. 
20. Aggregates were removed by discarding fractions 
within the void-volume peak. The limits of this 
aggregate peak were liberally estimated by inspecting 
the FPLC A280 trace. 
21. Fractions containing properly folded HI-IgAP were 
concentrated using a 30 kDa centrifugal concentrator to 
less than 1 mL. 
22. Protein was flash frozen in aliquots using liquid 
nitrogen. 
  
Figure 4.5.1 – Final HI-IgAP purity. 
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4.6 – Protein Validation 
 Even though the HI-IgAP purified from the second-generation denatured E. coli system 
was extremely pure and non-aggregated, further verification was needed to convince us that the 
protein was properly folded and biochemically identical to the enzyme purified from H. influenzae. 
The following four techniques confirmed that this was the first system to produce viable and 
recombinant HI-IgAP in sufficient biochemical amounts. 
a) Circular Dichroism 
 A circular dichroism (CD) spectrum of HI-IgAP was taken using a JASCO 815 CD 
Spectrometer. A 0.6 mg/mL solution of HI-IgAP buffered in 25 mM HEPES, pH 7.5 was scanned 
from 200 to 250 nm at 50 nm/min. The resulting spectrum is shown in Fig. 4.6.1.  
 The CD spectrum was submitted to the BeStSel server to calculate theoretical magnitudes 
of each secondary structure component.61 The fitted parameters indicate a strong parallel beta-
sheet signal (Table 4.6), which suggests a properly folded C-terminal beta helix based on the 










Table 4.6 – Theoretical model parameters for the HI-IgAP CD spectrum. The BeStSel server was used to generate 
a model based on differently weighted secondary structure elements.61 A scale factor of 2 was used for this model. 
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Figure 4.6.1 – CD spectrum of HI-IgAP. The experimental CD spectrum (left) shows a strong beta-sheet signal. The 
experimental data (red; right) were fit to a theoretical model (blue; right) based on weighted secondary structure elements. The 
fitting was done using the BeStSel server.61 Model residuals are shown in green and its parameters are summarized in Table 4.6. 
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b) Analytical Size-exclusion Chromatography 
 Analytical SEC was used to assess the ability of recombinant HI-IgAP to bind to IgA1. 
Recombinant inactive HI-IgAP and IgA1 (Athens Research) were injected onto an ENrich SEC650 
(Bio-Rad) column using a Biologic DuoFlow FPLC (Bio-Rad). The IgA1 peak of the inactive 
enzyme-substrate mixture eluted earlier than that of the free IgA1 peak (Fig. 4.6.2). As the 
concentrations of HI-IgAP and IgA1 were identical for all injections, the increase in absorbance 
for the IgA1 peak of the mixture also suggested that recombinant HI-IgAP bound IgA1. 
 
  
Figure 4.6.2 – Analytical SEC traces of the HI-IgAP-IgA1 interaction. 100 µL of 10 µM HI-IgAP 
(black) and 10 µM IgA1 (blue) were injected separately and at a 1:1 molar ratio (red). The SEC 
used 25 mM HEPES, pH 7.5 for its running buffer. 
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c) X-ray Crystallography 
 The ultimate test for confirming the validity of the protein-production system is to solve 
the HI-IgAP crystal structure using recombinant protein. Crystal drops were set up as previously 
described.20 The largest crystals formed from drops with HI-IgAP concentrations greater than 7 
mg/mL and PEG 20,000 concentrations less than 10% (w/v) (Fig. 4.6.3a). Small crystals were 
visible after two days of incubation. They were then left to grow for two weeks prior to diffraction. 
HI-IgAP crystals were cryo-cooled as previously described.20 Diffraction images were collected 
using a Rigaku rotating copper anode X-ray generator and an R-axis IV++ detector with a ten-
minute exposure time. Although they did not diffract very well (Fig. 4.6.3b), low-intensity and 
low-resolution diffraction peaks were visible. Synchrotron radiation and further optimization of 
the crystal conditions will likely allow us to collect a reasonable dataset to solve the crystal 
structure of the recombinant HI-IgAP. The fact that crystals with weak diffraction were 
successfully replicated strongly suggests the production of properly folded HI-IgAP.  
Figure 4.6.3 – HI-IgAP crystals. This figure shows the diffraction pattern (b) of a HI-IgAP crystal 
grown (a) under previously discovered crystal conditions. Low-resolution diffraction peaks were 
only visible when the crystal was exposed to prolonged radiation (10 minutes).  
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d) Enzymatic Activity 
 The activity of the SUMO-HI-IgAP construct was recently reconstituted by reverting the 
active-site point mutant back to the wild-type sequence (Appendices C and D). This was done 
with the services of GenScript USA. The active enzyme was then expressed and purified 
identically to the inactive mutant (Section 4.5) and showed activity following incubation with 
IgA1 (Fig. 4.6.4).  
Figure 4.6.4 – SUMO-HI-IgAP activity. This figure shows the activity of recombinantly expressed 
SUMO-HI-IgAP. Recombinant IgAP was incubated with IgA1 for 30 minutes at 37oC. 
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4.7 – Conclusions and Next Steps 
 My second-generation denatured E. coli system successfully produced recombinant HI-
IgAP, a task that has been unsuccessful ever since the crystal structure was solved a decade ago. 
The next step is to optimize the current HI-IgAP crystals to examine the binding sites of existing 
inhibitors by co-crystallization or crystal soaking. Improvements to existing small-molecule 
inhibitors can then be made using structure-based drug design strategies. Furthermore, the kinetic 
and thermodynamic parameters of the HI-IgAP can now be quantified and compared to other 
IgAPs and well-characterized proteases. 
 
Section 5 – Thesis Summary 
 Both HI-IgAP P. pastoris and E. coli protein production systems were able to successfully 
produce recombinant HI-IgAP. It is clear, however, that the second-generation denaturing E. coli 
system is vastly superior to the P. pastoris system, at least under laboratory-scale conditions. Given 
that the P. pastoris system still may be improved by reconsidering alternative transformation and 
expression methods (Section 3.6), particularly the use of a bioreactor, the most-suitable system for 
large-scale protein production has yet to be determined. This is assuming the enzyme can be 
redesigned as an IgAN therapeutic and scaling up becomes a necessity. 
This strategy of designing an expression construct with an N-terminal SUMO fusion with 
the intent performing denatured purification lends itself well to other problematic proteins that 
require native N-termini to properly fold. In particular, this strategy can be used to recombinantly 
produce the structurally homologous N. gonorrhoeae and N. meningitidis serine IgAPs, which also 
have the same N-terminal problem. 
With this new enzyme source, we can now begin to study the biochemical intricacies of 
the enzyme by interrogating the important questions surrounding HI-IgAP-IgA1 interactions and 
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Appendix B – Primary Sequence of the P. pastoris HI-IgAP Protein Fusion 
 



















Appendix C – Gene Sequence of the SUMO-HI-IgAP Construct 
The coding sequence for the inactive (A288) SUMO-HI-IgAP construct is shown below. This 
was the construct used for most of the experiments detailed in this thesis, with the exception of 
the activity assay in Section 4.6. The sequence of the active enzyme (S288) is the same as the 
















































Appendix D – Primary Sequence of the SUMO-HI-IgAP Construct 
The primary sequence for the inactive (A288) SUMO-HI-IgAP construct is shown below. This 
was the construct used for most of the experiments detailed in this thesis, with the exception of 
the activity assay in Section 4.6. The sequence of the active enzyme (S288) is the same as the 
one shown below but the residue in brackets is replaced by “S”. The His tag, SUMO, and HI-

















Appendix E – Expression and Purification ULP1 Protocol 
The following describes the protocol for ULP1 production. All pH values were measured at 
room temperature. All steps were performed at 4oC unless other specified. 
1. Grow an overnight ULP1 BL21(DE3) E. coli starter at 37oC from a glycerol stock. 
2. Inoculate 50 mL starter into each liter of LB media. 
3. Grow LB at 37oC until an OD600 of 0.6-0.9 and induce at 37oC with 1 mM IPTG for three 
hours. 
4. Harvest the cells by centrifugation at 6,000xg for 10 minutes. 
5. Resuspend the pellet in Resuspension Buffer until homogenous. 
6. Lyse the cells via two passes through a FRENCH pressure cell (Thermo) at 1100 psi. 
7. Centrifuge the lysate for one hour at 12,000xg and incubate the supernatant with Ni-
IMAC resin (NiNTA; Molecular Cloning Lab) pre-equilibrated in Resuspension Buffer 
for 1 hour at 4oC. 
8. Wash the resin with 1 L Wash Buffer then 1 L Resuspension Buffer. 
9. Elute the resin with Elution Buffer until an A280 reading of less than 0.05. 
10. The protein was concentrated to less than 5 mL using a 30 kDa MWCO centrifugal 
concentrator (Amicon) and loaded onto a Bio-Gel P-6DG desalting resin (Bio-Rad) pre-
equilibrated in Storage Buffer. 
11. Buffer-exchanged fractions were concentrated using a 30 kDa centrifugal concentrator to 
less than 1 mL and flash frozen in aliquots using liquid nitrogen. 
 
Buffer Name Components 
Resuspension 25 mM HEPES + 0.5 M NaCl + 10 mM imidazole + 2 mM TCEP 
Wash 25 mM HEPES + 0.1% (v/v) IgePal CA-630 + 10 mM imidazole + 2 mM TCEP 
Elution 25 mM HEPES + 0.5 M NaCl + 300 mM imidazole + 2 mM TCEP 
Storage 25 mM HEPES + 0.5 M NaCl + 2 mM TCEP 
Table E.1 – ULP1 purification buffers. HEPES, NaCl, and imidazole were purchased from BioBasic, TCEP from 
ChemImpex, and IgePal CA-630 from Sigma. All buffers have a pH of 7.5 at room temperature. All buffers were 
equilibrated to 4oC before use. TCEP was added to the buffer right before its use. 
